Drug Trial Radar · NCT05177835
Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
203
Planned (sponsor's estimate)
Start
Dec 3, 2021
Primary completion
Mar 2028
Study completion Apr 2028
Sponsor
- Lead sponsor
- Abivax S.A.Industry
- Sponsor type
- Industry
- First posted
- Jan 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label study aiming at evaluating the long-term safety and the efficacy profile of ABX464 given once a day (QD) at 25 mg in subjects who have been previously enrolled in the ABX464-102 or ABX464-104 studies (OLE and maintenance studies) and who are willing to continue their treatment. All subjects will receive ABX464 given at 25 mg QD. The enrolment in this long-term study will be based on the endoscopic improvement, the willingness of the subject to carry on his/her participation and also based on investigator's judgement. Subjects will be treated with ABX464 for a maximum period of 54 months. Subjects will be followed up quarterly. After the treatment period, subjects will be followed for 4 additional weeks for safety purposes.
Conditions
- Ulcerative Colitis
Interventions
ABX464Drug
All subjects will receive ABX464 given at 25 mg QD.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of adverse events in ABX464 treated subjectsTime frame: From Baseline to a maximum period of 78 months
Locations
46 sites in 14 countries. Site status is shown where the registry gives one.
Medizinische Universitaet Innsbruck
Innsbruck, Austria
Medical University of Vienna
Vienna, Austria
Antwerp University Hospital
Antwerp, Belgium
UZ Leuven
Leuven, Belgium
South Edmonton Gastroenterology
Edmonton, Canada
Fakultni nemocnice u sv. Anny v Brne
Brno, Czechia
Nemocnice Slany
Slaný, Czechia
Centre Hospitalier Universitaire Grenoble Alpes
Grenoble, France
Centre Hospitalier Universitaire De Montpellier
Montpellier, France
CHU Nantes - Hôtel Dieu
Nantes, France
Institut des MICI
Neuilly-sur-Seine, France
CHU Saint Etienne - Hôpital Nord
Saint-Etienne, France
Goethe University Frankfurt
Frankfurt, Germany
Studiengesellschaft BSF UG (haftungsbeschraenkt)
Halle, Germany
Medizinische Hochschule Hannover
Hanover, Germany
DRC Gyogyszervizsgalo Kozpont Kft.
Balatonfüred, Hungary
Semmelweis University
Budapest, Hungary
Vasutegeszseguegyi Nonprofit Koezhasznu Kft.
Debrecen, Hungary
Győr-Moson-Sopron Vármegyei Petz Aladár Egyetemi Oktató Kórház I. Belgyógyászat
Győr, Hungary
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy
Humanitas Mirasole S.p.A.
Rozzano, Italy
IRCCS Ospedale Sacro Cuore Don Calabria
Verona, Italy
Centrum Medyczne Plejady
Krakow, Poland
Samodzielny PZOZ w Lecznej
Łęczna, Poland
Niepubliczny Zaklad Opieki Zdrowotnej Neuromed M. i M. Nastaj sp. p
Lublin, Poland
Wojskowy Szpital Kliniczny w Lublinie
Lublin, Poland
Medicome Sp. z o. o.
Oświęcim, Poland
Trialmed CRS
Piotrkow Trybunalski, Poland
Termedia Sp. z o.o (NSZOZ Termedica - Centrum Badan Klinicznych)
Poznan, Poland
Ośrodek Badań Klinicznych "METABOLICA"
Tarnów, Poland
Medical Network Sp. z o.o.
Warsaw, Poland
Santa Sp. z o.o.
Warsaw, Poland
Centrum Badan Klinicznych Piotr Napora Lekarze Spolka Partnerska
Wroclaw, Poland
Centrum Medyczne Oporow
Wroclaw, Poland
LexMedica
Wroclaw, Poland
Kliničko bolnički centar Zvezdara
Belgrade, Serbia
Opšta bolnica "Đorđe Joanović" Zrenjanin Odsek za gastroenterologiju
Zrenjanin, Serbia
Cliniq s.r.o.
Bratislava, Slovakia
GASTRO I, s.r.o.
Prešov, Slovakia
Endomed s.r.o
Vranov nad Topľou, Slovakia
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.